Conditions: Hypoxic-Ischemic Encephalopathy; Neonatal Encephalopathy Interventions: Behavioral: Holding; Other: Saliva collection; Behavioral: No Holding Sponsor: Maine Medical Center Recruiting
Conditions: Diabetes Mellitus, Type 2; Coronary Artery Disease Interventions: Dietary Supplement: Trans-resveratrol; Dietary Supplement: Placebo Sponsors: Maine Medical Center; American Heart Association Recruiting
Condition: Chronic Pain Intervention: Other: Interactive decision support tool Sponsors: Shared Decision Making Resources; University of New England; Pfizer Enrolling by invitation
Condition: Heart Failure With Normal Ejection Fraction Interventions: Dietary Supplement: Active lozenge; Drug: Placebo Sponsors: Penobscot Bay Medical Center; HumanN Completed
Condition: Arthropathy of Hip Interventions: Drug: Vecuronium 0.1 mg/kg; Drug: Vecuronium 0.2mg/kg Sponsors: Craig Curry; Maine Medical Center; Spectrum Medical Group Anesthesiology Completed
Condition: Orthopedic Disorder Interventions: Other: glenohumeral mobilization-oscillation; Other: glenohumeral mobilization-sustained Sponsor: University of New England Completed
Condition: Knee Osteoarthritis Interventions: Drug: Femoral Nerve Catheters; Drug: Single Shot Femoral Nerve Blocks Sponsor: Eastern Maine Medical Center Completed
Condition: Reaction to Severe Stress, Unspecified Interventions: Other: Tyrosine-Containing Food Bar; Other: Placebo Bar Sponsor: United States Army Research Institute of Environmental Medicine Completed
Condition: Neonatal Abstinence Syndrome Interventions: Drug: Methadone; Drug: Diluted Deodorized Tincture of Opium Sponsor: Eastern Maine Medical Center Completed
Conditions: Prodromal Schizophrenia; Psychotic Disorders; Severe Bipolar Disorder With Psychotic Features; Severe Major Depression With Psychotic Features Interventions: Behavioral: Family-aided Assertive Community Treatment; Behavioral: Enhanced standard treatment Sponsors: Maine Medical Center; Columbia University; Harvard University; University of California, Irvine Completed
Condition: Healthy Interventions: Drug: Vasopressin, Arginine, ADH; Drug: Placebo; Sterile Saline Sponsors: Bowdoin College; Maine Medical Center; National Institute of Mental Health (NIMH) Completed
Conditions: Blood Stream Infections; MRSA Infections Intervention: Behavioral: healthcare staff processes for infection prevention Sponsors: Maine Medical Center Research Institute; Agency for Healthcare Research and Quality (AHRQ); Indiana University School of Medicine Completed
Conditions: Acute Kidney Insufficiency; Acute Renal Insufficiency; Acute Kidney Injury; Ischemic Preconditioning Intervention: Procedure: Remote Ischemic Preconditioning Sponsor: Maine Medical Center Research Institute Unknown status
Conditions: Chronic Disease; Arthritis; Uterine Diseases; Spinal Diseases; Preventive Health Services Interventions: Behavioral: Enhanced Support; Behavioral: Usual-Support Sponsors: Health Dialog; Health Net California; Highmark Blue Cross Blue Shield Completed
Conditions: Chronic Kidney Disease; End Stage Kidney Disease; Cardiovascular Disease Intervention: Behavioral: exercise training Sponsor: Maine Medical Center Completed
Conditions: Nephrolithiasis; Ureteral Calculi Interventions: Drug: tamsulosin; Drug: Standard therapy with ibuprofen and oxycodone. Sponsors: Maine Medical Center; Maine Medical Center Mentored Research Committee Completed
Conditions: Hypertriglyceridemia (TG>200<500); Hyperlipidemia; Coronary Artery Disease; Coronary Risk Equivalent; Diabetes Intervention: Drug: docosahexanoic acid (DHA) Sponsor: Maine Center for Lipids and Cardiovascular Health Completed
Conditions: Child Development Disorders; Pregnancy; Subclinical Hypothyroidism Intervention: Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Unknown status
Conditions: Smith-Lemli-Opitz Syndrome; Pregnancy Intervention: Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Completed
Conditions: Osteopenia; Osteoporosis Interventions: Drug: Teriparatide; Drug: Placebo teriparatide Sponsors: University of California, San Francisco; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Completed
Condition: Postural Balance Interventions: Other: Balancing Act exercise curriculum; Other: Informational Brochure Sponsors: University of Maine; University of New England; National Institutes of Health (NIH); National Institute on Aging (NIA) Completed
Condition: Otitis Media With Effusion Intervention: Procedure: osteopathic manipulative medicine (OMM) Sponsors: West Virginia School of Osteopathic Medicine; University of New England; American Academy of Osteopathy; Osteopathic Research Center Completed
Conditions: Frail Elderly; Cognitive Impairment; Mobility Limitation; Depressive Symptoms Interventions: Behavioral: Tai Ji Quan: Moving for Better Balance; Behavioral: Behavioral Activation; Other: Resource Navigation; Other: Enhanced Usual Care Sponsors: University of Vermont; Central Vermont Medical Center; Dartmouth College; Dartmouth-Hitchcock Medical Center; Maine Medical Center; MaineGeneral Health; Maine-Dartmouth Family Medicine Residency; Dartmouth SYNERGY Clinical and Translational Science Institute; Northern New England Clinical and Translational Research Network Recruiting
Condition: Cancer Interventions: Behavioral: Attention control (reading); Behavioral: Touch, Caring and Cancer DVD program Sponsors: Collinge and Associates, Inc.; National Cancer Institute (NCI) Completed
Conditions: Cardiovascular Disease; Surgery Intervention: Other: Quality improvement intervention Sponsors: Dartmouth-Hitchcock Medical Center; Maine Medical Center; Catholic Medical Center; Somanetics Corporation; LivaNova; Maquet Cardiovascular; Northern New England Cardiovascular Disease Study Group; Luna Innovations; Agency for Healthcare Research and Quality (AHRQ) Completed
Condition: Epilepsy Intervention: Behavioral: Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH) Sponsors: Dartmouth-Hitchcock Medical Center; Centers for Disease Control and Prevention Active, not recruiting
Condition: Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy Intervention: Drug: Cenobamate Sponsor: SK Life Science, Inc. Enrolling by invitation
Condition: Breast Cancer Interventions: Behavioral: YWI; Behavioral: Physical Activity Sponsors: Dana-Farber Cancer Institute; American Society of Clinical Oncology Completed
Condition: Osteoporosis Interventions: Drug: PTH; Drug: Alendronate Sponsors: Dennis Black; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Completed
Condition: Ovarian Cancer Interventions: Other: Fourier transform ion cyclotron resonance mass spectrometry; Other: chromatography; Other: diagnostic laboratory biomarker analysis; Other: questionnaire administration Sponsor: Pine Street Foundation Completed
Condition: Colorectal Cancer Screening Interventions: Behavioral: Notification; Behavioral: Training Sponsors: Massachusetts General Hospital; Maine Medical Center; Brigham and Women's Hospital; Newton-Wellesley Hospital; North Shore Medical Center Enrolling by invitation
Conditions: Peripheral Artery Disease; Critical Limb Ischemia; Claudication Interventions: Other: standard gauze dressing; Other: Prevena Incision Management system Sponsors: University of Vermont Medical Center; KCI USA, Inc.; Maine Medical Center; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center; Dartmouth-Hitchcock Medical Center Recruiting
Conditions: Coronary Artery Disease; Overweight Interventions: Drug: Salsalate; Drug: Placebo Sponsors: Joslin Diabetes Center; Beth Israel Deaconess Medical Center; Tufts Medical Center; National Heart, Lung, and Blood Institute (NHLBI) Completed
Conditions: Intervention Schools (Schools Receiving RPI); Control Schools (Schools Not Receiving RPI) Intervention: Behavioral: Restorative Practices Intervention Sponsors: RAND; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Completed
Condition: Psychosocial Effects of Cancer and Its Treatment Intervention: Procedure: psychosocial assessment and care Sponsors: Inflexxion, Inc.; National Cancer Institute (NCI) Unknown status
Condition: Previously Treated Non-Small Cell Lung Cancer Intervention: Drug: Screening Platform Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Conditions: Extensive Stage Lung Small Cell Carcinoma; Recurrent Lung Small Cell Carcinoma Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Etoposide; Biological: Nivolumab Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Metastatic Malignant Neoplasm in Lymph Node; Metastatic Malignant Neoplasm in the Adrenal Gland; Metastatic Malignant Neoplasm in the Lung; Metastatic Malignant Neoplasm in the Pancreas; Metastatic Malignant Neoplasm in the Skin; Metastatic Malignant Neoplasm in the Soft Tissues; Metastatic Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage II Renal Cell Cancer AJCC v7; Stage III Renal Cell Cancer AJCC v7; Unclassified Renal Cell Carcinoma Interventions: Procedure: Conventional Surgery; Biological: Nivolumab; Other: Patient Observation; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group Recruiting
Conditions: Invasive Breast Carcinoma; Stage 0 Breast Cancer AJCC v6 and v7; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma Interventions: Other: Laboratory Biomarker Analysis; Other: Patient Observation; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy Sponsor: National Cancer Institute (NCI) Recruiting
Condition: Node Positive HER2 Negative Breast Cancer Interventions: Other: Placebo; Drug: Aspirin Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); United States Department of Defense; Bayer; Canadian Cancer Trials Group Recruiting
Condition: Breast Carcinoma Interventions: Other: Health Education Program; Other: Weight Loss Intervention Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Division of Cancer Control; NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP); Canadian Cancer Trials Group Recruiting
Condition: Breast Cancer Interventions: Radiation: Radiation; Other: No Radiation Sponsors: Canadian Cancer Trials Group; Alliance for Clinical Trials in Oncology; Eastern Cooperative Oncology Group; NRG Oncology; Southwest Oncology Group Recruiting
Conditions: Dyspnea; Fatigue; Nausea and Vomiting; Pain; Stage IV Breast Cancer Interventions: Radiation: Stereotactic Radiosurgery; Procedure: Therapeutic Conventional Surgery; Other: Laboratory Biomarker Analysis Sponsors: NRG Oncology; National Cancer Institute (NCI) Recruiting
Conditions: Breast Adenocarcinoma; HER2/Neu Negative; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 Interventions: Drug: Entinostat; Drug: Exemestane; Drug: Goserelin; Drug: Goserelin Acetate; Other: Placebo Administration; Other: Quality-of-Life Assessment Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7 Interventions: Drug: Cyclophosphamide; Drug: Docetaxel; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel; Other: Quality-of-Life Assessment; Biological: Trastuzumab Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Stage II Breast Cancer; Stage IIIA Breast Cancer Interventions: Procedure: Axillary Lymph Node Dissection (ALND); Radiation: Nodal Radiation Therapy; Radiation: Axillary Radiation Therapy Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group Suspended
Conditions: Ductal Breast Carcinoma In Situ; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma Interventions: Drug: Anastrozole; Drug: Exemestane; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Other: Quality-of-Life Assessment; Drug: Systemic Chemotherapy; Drug: Tamoxifen Citrate Sponsor: National Cancer Institute (NCI) Active, not recruiting
Condition: Stage II Prostate Adenocarcinoma Interventions: Radiation: Intensity-Modulated Radiation Therapy (IMRT); Radiation: Stereotactic Body Radiation Therapy (SBRT) Sponsors: NRG Oncology; National Cancer Institute (NCI) Recruiting
Condition: Breast Cancer Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Docetaxel; Drug: Paclitaxel Sponsors: NSABP Foundation Inc; National Cancer Institute (NCI) Active, not recruiting
Conditions: Breast Carcinoma Metastatic in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma Interventions: Drug: Cisplatin; Other: Laboratory Biomarker Analysis; Other: Placebo Administration; Drug: Veliparib Sponsor: National Cancer Institute (NCI) Active, not recruiting
Conditions: Metastatic Cutaneous Melanoma; Metastatic Non-Cutaneous Melanoma; Non-Cutaneous Melanoma; Recurrent Cutaneous Melanoma; Recurrent Non-Cutaneous Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage III Mucosal Melanoma of the Head and Neck AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Stage IVA Mucosal Melanoma of the Head and Neck AJCC v7; Stage IVB Mucosal Melanoma of the Head and Neck AJCC v7; Stage IVC Mucosal Melanoma of the Head and Neck AJCC v7 Interventions: Biological: Ipilimumab; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Biological: Recombinant Interferon Alfa-2b Sponsor: National Cancer Institute (NCI) Active, not recruiting
Condition: Colorectal Cancer Interventions: Drug: celecoxib; Drug: 5-fluorouracil; Other: placebo; Drug: oxaliplatin; Drug: leucovorin Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Active, not recruiting
Conditions: Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma Interventions: Drug: Capecitabine; Drug: Carboplatin; Drug: Cisplatin; Other: Laboratory Biomarker Analysis; Procedure: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI) Recruiting
Condition: Kidney Cancer Interventions: Drug: everolimus; Other: placebo Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Active, not recruiting
Condition: Pegfilgrastim-induced Back and Leg Pain Interventions: Drug: Loratadine; Drug: placebo Sponsors: University of Vermont; Cancer and Leukemia Group B Unknown status
Conditions: Breast Adenocarcinoma; Estrogen Receptor and/or Progesterone Receptor Positive; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage IIIB Breast Cancer AJCC v7 Interventions: Drug: Anastrozole; Drug: Exemestane; Other: Laboratory Biomarker Analysis; Drug: Letrozole; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Drug: Tamoxifen Citrate Sponsors: National Cancer Institute (NCI); American College of Surgeons; Cancer and Leukemia Group B; NSABP Foundation Inc; NCIC Clinical Trials Group; North Central Cancer Treatment Group; Southwest Oncology Group Active, not recruiting
Conditions: Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer AJCC v6 and v7; Stage II Renal Cell Cancer AJCC v7; Stage III Renal Cell Cancer AJCC v7 Interventions: Other: Laboratory Biomarker Analysis; Other: Placebo; Other: Quality-of-Life Assessment; Drug: Sorafenib Tosylate; Drug: Sunitinib Malate Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; NCIC Clinical Trials Group; Southwest Oncology Group Completed
Condition: Multiple Myeloma in Relapse Interventions: Drug: pomalidomide; Drug: ixazomib; Drug: dexamethasone Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Celgene Corporation; Millennium Pharmaceuticals, Inc. Recruiting
Conditions: Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Invasive Ductal Breast Carcinoma; Invasive Lobular Breast Carcinoma; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer Interventions: Drug: fulvestrant; Drug: anastrozole Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI) Active, not recruiting
Conditions: Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma Interventions: Biological: Bevacizumab; Biological: Ipilimumab Sponsor: National Cancer Institute (NCI) Active, not recruiting
Condition: Ductal Breast Carcinoma In Situ Interventions: Other: Laboratory Biomarker Analysis; Biological: Trastuzumab; Radiation: Whole Breast Irradiation Sponsors: National Cancer Institute (NCI); NRG Oncology Active, not recruiting
Conditions: Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer Interventions: Drug: enzalutamide; Drug: abiraterone; Drug: prednisone Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Astellas Pharma US, Inc.; Medivation, Inc.; Biologics, Inc. Active, not recruiting
Conditions: Breast Cancer; Precancerous Condition Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: Excess human biological tissue; Procedure: quality-of-life assessment Sponsors: University of Nebraska; National Cancer Institute (NCI) Completed
Conditions: Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Small Cell Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7 Interventions: Drug: Cisplatin; Drug: Etoposide; Drug: Veliparib; Drug: Placebo Sponsor: National Cancer Institute (NCI) Completed
Conditions: Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer Interventions: Biological: Bevacizumab; Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Drug: Paclitaxel; Other: Placebo Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; ECOG-ACRIN Cancer Research Group; North Central Cancer Treatment Group Active, not recruiting
Condition: Breast Cancer Interventions: Drug: Letrozole; Other: Placebo Sponsors: NSABP Foundation Inc; National Cancer Institute (NCI); Novartis Active, not recruiting
Conditions: Diffuse Large B-Cell Lymphoma; Double-Expressor Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Etoposide; Drug: Prednisone; Biological: Rituximab; Drug: Venetoclax; Drug: Vincristine; Drug: Vincristine Sulfate Sponsor: National Cancer Institute (NCI) Recruiting